Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
Details : Camlipixant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cough.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Camlipixant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cough.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Camlipixant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cough.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : GSK
Deal Size : $2,000.0 million
Deal Type : Acquisition
GSK Completes Acquisition of BELLUS Health
Details : The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $2,000.0 million
June 28, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : GSK
Deal Size : $2,000.0 million
Deal Type : Acquisition
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Details : Camlipixant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cough.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : GSK
Deal Size : $2,000.0 million
Deal Type : Acquisition
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company BELLUS Health
Details : The acquisition provides GSK access to BLU-5937 (camlipixant), a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $2,000.0 million
April 18, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : GSK
Deal Size : $2,000.0 million
Deal Type : Acquisition
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 (camlipixant) is an investigational P2X3 antagonist, for the treatment of refractory chronic cough. Clinical evidence have linked the P2X3 receptor and refractory chronic cough to a sensory nerve dysfunction that can lead to cough hypersensitivi...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. It is being developed for the treatment of refractory chronic cough.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2022
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Camlipixant
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable